FDA Puts Achillion Pharmaceuticals, Inc. Hepatitis C Drug on Clinical Hold

Published: Jul 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Achillion Pharmaceuticals Inc. (ACHN) said U.S. regulators put a hold on a clinical trial of one of the company’s experimental drugs for hepatitis C after some patients experienced elevated liver enzymes. The company’s shares declined in extended trading after the announcement.

Help employers find you! Check out all the jobs and post your resume.

Back to news